(Q40707649)

22 September 2017

title

Response to peginterferon-alpha 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 1. (English)

1 reference

22 September 2017

1 reference

7

Keiichi Fujiwara

1 reference

22 September 2017

Tomoo Miyauchi

1

1 reference

22 September 2017

Tatsuo Kanda

2

1 reference

22 September 2017

Fumio Imazeki

3

1 reference

22 September 2017

Rintaro Mikata

4

1 reference

22 September 2017

Akinobu Tawada

5

1 reference

22 September 2017

Makoto Arai

6

1 reference

22 September 2017

Shingo Nakamoto

8

1 reference

22 September 2017

Shuang Wu

9

1 reference

22 September 2017

Takeshi Tanaka

10

1 reference

22 September 2017

Tatsuo Miyamura

11

1 reference

22 September 2017

Michio Kimura

12

1 reference

22 September 2017

Yasuo Hirai

13

1 reference

22 September 2017

Motohide Takashi

14

1 reference

22 September 2017

Shigeru Mikami

15

1 reference

22 September 2017

Nobuyuki Sugiura

16

1 reference

22 September 2017

Yutaka Natsuki

17

1 reference

22 September 2017

Ryosaku Azemoto

18

1 reference

22 September 2017

Noriaki Suzuki

19

1 reference

22 September 2017

Osamu Yokosuka

20

1 reference

22 September 2017

publication date

10 February 2012

1 reference

22 September 2017

published in

Hepatology international

1 reference

22 September 2017

volume

7

1 reference

22 September 2017

issue

1

1 reference

22 September 2017

page(s)

144-152

1 reference

Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

New antiviral therapies for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

Response to peginterferon-alfa 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

Predictive factors for response to peginterferon-alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

Gender influence on treatment of chronic hepatitis C genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: the null responder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

Quantification of hepatitis C virus in patients treated with peginterferon-alfa 2a plus ribavirin treatment by COBAS TaqMan HCV test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

Sequence variability in the 5' non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

Changing trends in hepatitis C infection over the past 50 years in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

Efficacy of peginterferon-alpha-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

Hepatitis C treatment response kinetics and impact of baseline predictors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

Identifying HCV genotype 1 patients at risk of relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

A new era of hepatitis C therapy begins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12072-012-9349-4

Optimal therapy of hepatitis C.

21 January 2018

1 reference

12 December 2020

Should aged patients with chronic hepatitis C be treated with interferon and ribavirin combination therapy?

1 reference

12 December 2020

Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C: an analysis using the propensity score

1 reference

12 December 2020

Significance of specific antibody assay for genotyping of hepatitis C virus

1 reference

12 December 2020

Hepatitis C and hepatocellular carcinoma

1 reference

12 December 2020

10.1007/S12072-012-9349-4

Identifiers

DOI

1 reference

22 September 2017

1 reference